Firstly, we separated CTCs in clinical samples by size effect of microfluidic chips and found that EpCAM/EGFR/Her2 were widely presented as biomarkers in CTCs from peripheral blood of various cancer patients. This evidence concerns the gene EPCAM and cancer.